Physician profile
Robert Joseph Jantz
NPI 1396751749
$3,727.18
in general payments reported to CMS, 2019-2025
31 companies · $418 in 2025
The $418 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $283 · 2020: $407 · 2021: $497 · 2022: $897 · 2023: $500 · 2024: $725 · 2025: $418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,643.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,643.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $765.89 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $602.88 | 2021-2025 | |
| Glaxosmithkline, LLC. | $426.75 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $422.98 | 2020-2025 | Airsupra, Breztri, Farxiga |
| Inspire Medical Systems, INC. | $203.38 | 2024-2025 | Inspire |
| Novartis Pharmaceuticals Corporation | $159.19 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $133.97 | 2020-2025 | Xifaxan, Trulance |
| Teva Pharmaceuticals USA, INC. | $110.89 | 2019-2024 | Austedo Xr |
| Lilly USA, LLC | $97.12 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $93.22 | 2023-2024 | Cologuard Collection Kit |
| Allergan, INC. | $87.63 | 2020-2021 | |
| Abbott Laboratories | $68.68 | 2021-2023 | Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $57.14 | 2019-2023 | Verquvo, Steglatro, Belsomra |
| Kowa Pharmaceuticals America, INC. | $56.50 | 2021-2022 | |
| Amgen INC. | $48.62 | 2019-2025 | Krystexxa |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $46.97 | 2022 | |
| Pfizer INC. | $44.81 | 2023 | |
| Antares Pharma, INC. | $44.44 | 2023-2024 | Xyosted, Nocdurna, Tlando |
| Hologic Sales and Service, LLC | $43.12 | 2022-2024 | Aptima |
| Shield Therapeutics INC | $30.72 | 2022-2023 | Accrufer |
| Astellas Pharma US INC | $27.81 | 2021-2024 | Veozah |
| Biohaven Pharmaceuticals, INC. | $20.38 | 2021 | |
| Verrica Pharmaceuticals INC. | $17.83 | 2024 | Ycanth |
| Corcept Therapeutics | $17.09 | 2025 | Korlym |
| Takeda Pharmaceuticals U.S.A., INC. | $15.63 | 2021 | |
| Alexion Pharmaceuticals, INC. | $15.59 | 2023 | Strensiq |
| Bayer Healthcare Pharmaceuticals INC. | $14.90 | 2021 | |
| Horizon Therapeutics Plc | $14.88 | 2023 | Krystexxa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.80 | 2024 | Caplyta |
| Xeris Pharmaceuticals, INC. | $13.31 | 2021 | |
| Amarin Pharma, INC. | $11.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Jantz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.